15 Nov 2016

The Lancet Publishes First Head-to-Head Study of Cimzia® (certolizumab pegol) and Humira® (adalimumab) in Bio-Naïve Rheumatoid Arthritis Patients

Read More
14 Nov 2016

Results from Phase 3 Bridge study showed romosozumab significantly increased bone mineral density in men with Osteoporosis

Read More
11 Nov 2016

UCB’s anti-epileptic drug VIMPAT® (lacosamide) receives positive opinion by EU CHMP as monotherapy for patients with partial-onset seizures

Read More
11 Nov 2016

UCB showcases advancements in its late stage immunology portfolio through innovative research at 2016 ACR/ARHP Annual Meeting

Read More
7 Nov 2016

Transparency notifications

Read More
25 Oct 2016

UCB continues its growth path

Read More
21 Oct 2016

Transparency notification

Read More
7 Oct 2016

Transparency notification

Read More
3 Oct 2016

CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

Read More
26 Sep 2016

UCB and Amgen announce U.S. FDA acceptance of biologics licence application for Romosozumab

Read More
Subscribe to